Cellinfinity Bio
Cellinfinity Bio is a biotechnology company focused on developing advanced cell therapies for solid tumors by harnessing evolutionary principles to genetically reprogram immune cells in the body. Their proprietary technology addresses key challenges in cell therapy, such as inefficient and costly autologous CAR-T manufacturing and the immunosuppressive tumor microenvironment. They offer innovative solutions including Supercharged In Vivo Cell Therapy™, which simplifies manufacturing by enabling in situ engineering of T cells, and a robust pipeline featuring in vivo CAR-T and autologous CAR-T therapies targeting novel solid tumor antigens. The company integrates scFv evolution, vector evolution, CAR design optimization, and genomic enhancements to improve delivery, safety, specificity, and T cell function, positioning them as a leader in next-generation immunotherapies for solid tumors. Their pipeline includes preclinical candidates and collaborations, supported by published and licensed key technologies in CAR design and gene delivery.
Cellinfinity Bio
Cellinfinity Bio is a biotechnology company focused on developing advanced cell therapies for solid tumors by harnessing evolutionary principles to genetically reprogram immune cells in the body. Their proprietary technology addresses key challenges in cell therapy, such as inefficient and costly autologous CAR-T manufacturing and the immunosuppressive tumor microenvironment. They offer innovative solutions including Supercharged In Vivo Cell Therapy™, which simplifies manufacturing by enabling in situ engineering of T cells, and a robust pipeline featuring in vivo CAR-T and autologous CAR-T therapies targeting novel solid tumor antigens. The company integrates scFv evolution, vector evolution, CAR design optimization, and genomic enhancements to improve delivery, safety, specificity, and T cell function, positioning them as a leader in next-generation immunotherapies for solid tumors. Their pipeline includes preclinical candidates and collaborations, supported by published and licensed key technologies in CAR design and gene delivery.